MedTrace Logo

An Efficacy Study Of Ortataxel In Recurrent Glioblastoma

NCT01989884 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2019-10-23

No results posted yet for this study

Summary

Italian Study On The Efficacy Of Ortataxel In Recurrent Glioblastoma

Conditions

Interventions

DRUG

Ortataxel

75 mg/m2, IV (in the vein) every 21 days. Number of Cycles: until progression or unacceptable toxicity develops.

Sponsors & Collaborators

  • Mario Negri Institute for Pharmacological Research

    lead OTHER

Principal Investigators

  • Antonio Silvani, MD · Fondazione IRCCS Istituto Neurologico "Carlo Besta" di Milano

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-11-30
Primary Completion
2015-12-31
Completion
2016-12-31

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01989884 on ClinicalTrials.gov